• Molecular NameSunitinib
  • SynonymSU11248; Sunitinib malate; Sutent
  • Weight398.482
  • Drugbank_IDDB01268
  • ACS_NO341031-54-7
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.59
  • pka8.95
  • LogD (pH=7, predicted)1.45
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.11
  • LogSw (predicted, AB/LogsW2.0)0.03
  • Sw (mg/ml) (predicted, ACD/Labs)0.03
  • No.of HBond Donors3
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds7
  • TPSA77.23
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability54.5
  • Protein binding95.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmSunitinib is metabolized primarily by the cytochrome P450 enzyme, CYP3A4, to produce its primary active metabolite, which is further metabolized by CYP3A4.
  • Half life40~60 h (sunitinib); 80~110 h (metabolite)
  • ExcretionFecal (61%) and renal (16%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityDiarrhea, hypertension, bleeding, mucositis, skin abnormalities, and altered taste were more common in patients receiving Sunitinib than it those receiving placebo.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A